Brainstorm Cell - BCLI Operating Margin

Brainstorm Cell (BCLI) is scaling final tests of its ALS cell therapy for accelerated FDA approval. The operating profit margin helps track the dynamics of this sector, where the current status is 0.00. Brainstorm Cell (BCLI) is developing Alzheimer's therapy platforms, relying on external investments and grants. The absence of recurring revenue ties the business's financial stability exclusively to the results of clinical trials.
Comprehensive metric breakdowns and analytics for Brainstorm Cell (BCLI)

When constructing a long-term portfolio, fundamental screening requires an analysis of cost management efficiency relative to revenue. This operating profit margin measures the share of operating income before financial expenses and taxes, which is critical for Brainstorm Cell (BCLI) given its dependence on FDA approval for ALS therapy, allowing for an assessment of the business model's resilience based on current liquidity reserves.